Sunho Biologics Inc

Sunho Biologics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of biologics that regulate the immune microenvironment by modulating innate and adaptive immunity. Its lead candidate, IAH0968, is an antibody-dependent cell-mediated cytotoxicity-enhanced monoclonal antibody in Phase II trials for biliary tract carcinoma and colorectal cancer (CRC). The company also has IAP0971 and IAE0972 immunocytokines, which have completed Phase I trials for advanced solid tumors including non-small cell lung cancer and CRC. Its preclinical pipeline includes IBB0979, IBC0966, IBD0333, IAN0982, ISH0988, and ISH0613. Founded in 2018 and headquartered in Huzhou, China, Sunho Biologics is a subsidiary of Sunho Wisdom Investments Limited.